Trust Co. of Toledo NA OH Lowers Stake in GSK plc (NYSE:GSK)

Trust Co. of Toledo NA OH cut its position in shares of GSK plc (NYSE:GSK) by 14.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,873 shares of the pharmaceutical company’s stock after selling 4,806 shares during the quarter. Trust Co. of Toledo NA OH’s holdings in GSK were worth $943,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC grew its stake in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its stake in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the period. Clifford Capital Partners LLC boosted its stake in shares of GSK by 14.3% in the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the period. Cerity Partners LLC boosted its stake in shares of GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the period. Finally, Natixis Advisors LLC boosted its stake in shares of GSK by 20.0% in the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after purchasing an additional 83,433 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GSK has been the subject of several analyst reports. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price objective for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Down 1.1 %

Shares of NYSE:GSK opened at $32.71 on Tuesday. The stock has a market capitalization of $67.79 billion, a price-to-earnings ratio of 21.24, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63. GSK plc has a 1-year low of $32.55 and a 1-year high of $45.92. The company’s fifty day moving average is $34.30 and its two-hundred day moving average is $38.12. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Investors of record on Friday, November 15th were issued a $0.3928 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.80%. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 95.45%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.